Other MEK inhibitors, however, like U0126, PD-0325901, and selumetinib, could not eliminate melanoma cells carrying MEK1T55delinsRT (Supplementary Fig S6), despite the fact that these MEK inhibitors share the mode of action with trametinib: They all are non-competitive with ATP inhibitors, binding MEK1 adjacent to the ATP-binding site (Gilmartin et al, 2011). Here, MAP2K1 is linked to melanoma.